Pioglitazone acutely stimulates adiponectin secretion from mouse and human adipocytes via activation of the phosphatidylinositol 3′-kinase

Life Sciences

Volumn 83, Issue 19-20, 2008, Pages 638-643

  Pereira, Rocio I ^a,b   Leitner, J Wayne ^a   Erickson, Christopher ^b   Draznin, Boris ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Adiponectin regulation; Insulin signaling; Thiazolidinediones

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ADIPONECTIN; DACTINOMYCIN; GLITAZONE DERIVATIVE; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PIOGLITAZONE; WORTMANNIN;

ADIPOCYTE; ANIMAL CELL; ARTICLE; CELL STRAIN 3T3; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; THIN LAYER CHROMATOGRAPHY; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; 3T3-L1 CELLS; ADIPOCYTES; ADIPONECTIN; ANDROSTADIENES; ANIMALS; BLOTTING, WESTERN; CELL LINE; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN ANTAGONISTS; MALE; MICE; THIAZOLIDINEDIONES; TRANSCRIPTION, GENETIC;

MURINAE;

EID: 54949138357     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2008.09.002     Document Type: Article

References (32)

1. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., Hotta K., Shimomura I., Nakamura T., Miyaoka K., Kuriyama H., Nishida M., Yamashita S., Okubo K., Matsubara K., Muraguchi M., Ohmoto Y., Funahashi T., and Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochemical and Biophysiological Research Communications 257 (1999) 79-83
2. Barbour L.A., Mizanoor R.S., Gurevich I., Leitner J.W., Fischer S.J., Roper M.D., Knotts T.A., Vo Y., McCurdy C.E., Yakar S., Leroith D., Kahn C.R., Cantley L.C., Friedman J.E., and Draznin B. Increased P85alpha is a potent negative regulator of skeletal muscle insulin signaling and induces in vivo insulin resistance associated with growth hormone excess. Journal of Biological Chemistry 280 (2005) 37489-37494
3. Berg A.H., Combs T.P., Du X., Brownlee M., and Scherer P.E. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nature Medicine 7 8 (2001) 947-953
4. Bodles A.M., Banga A., Rasouli N., Ono F., Kern P.A., and Owens R.J. Pioglitazone increases secretion of high-molecular-weight adiponectin from adipocytes. American Journal of Physiology- Endocrinology and Metabolism 291 5 (2006) 10.1152/ajpendo.00187
5. Bogan J.S., and Lodish H.F. Two compartments for insulin-stimulated exocytosis in 3T3-L1 adipocytes defined by endogenous ACRP30 and GLUT4. Journal of Cell Biology 146 (1999) 609-620
6. Cesari M., Pessina A.C., Zanchetta M., De Toni R., Avogaro A., Pedon L., Dorigatti F., Maiolino G., and Rossi G.P. Low plasma adiponectin is associated with coronary artery disease but not with hypertension in high-risk nondiabetic patients. Journal of Internal Medicine 260 (2006) 474-483
7. Choi K.M., Lee J., Lee K.W., Seo J.A., Oh J.H., Kim S.G., Kim N.H., Choi D.S., and Baik S.H. Serum adiponectin concentrations predict the developments of type 2 diabetes and the metabolic syndrome in elderly Koreans. Clinical Endocrinology (Oxford) 61 (2004) 75-80
8. Combs T.P., Wagner J.A., Berger J., Doebber T., Wang W.J., Zhang B.B., Tanen M., Berg A.H., O'Rahilly S., Savage D.B., Chatterjee K., Weiss S., Larson P.J., Gottesdiener K.M., Gertz B.J., Charron M.J., Scherer P.E., and Moller D.E. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 143 (2002) 998-1007
9. Cruz M., Garcia-Macedo R., Garcia-Valerio Y., Gutierrez M., Medina-Navarro R., Duran G., Wacher N., and Kumate J. Low adiponectin levels predict type 2 diabetes in Mexican children. Diabetes Care 27 (2004) 1451-1453
10. Fasshauer M., Klein J., Neumann S., Eszlinger M., and Paschke R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochemical and Biophysiological Research Communications 290 (2002) 1084-1089
11. Fruebis J., Tsao T.S., Javorschi S., Ebbets-Reed D., Erickson M.R., Yen F.T., Bihain B.E., and Lodish H.F. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proceedings of the National Academy of Sciences of the United States of America 98 (2001) 2005-2010
12. Hotta K., Funahashi T., Arita Y., Takahashi M., Matsuda M., Okamoto Y., Iwahashi H., Kuriyama H., Ouchi N., Maeda K., Nishida M., Kihara S., Sakai N., Nakajima T., Hasegawa K., Muraguchi M., Ohmoto Y., Nakamura T., Yamashita S., Hanafusa T., and Matsuzawa Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arteriosclerosis Thrombosis and Vascular Biology 20 (2000) 1595-1599
13. Hu E., Liang P., and Spiegelman B.M. AdipoQ is a novel adipose-specific gene dysregulated in obesity. Journal of Biological Chemistry 271 (1996) 10697-10703
14. Iwaki M., Matsuda M., Maeda N., Funahashi T., Matsuzawa Y., Makishima M., and Shimomura I. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52 (2003) 1655-1663
15. Kojima S., Funahashi T., Otsuka F., Maruyoshi H., Yamashita T., Kajiwara I., Shimomura H., Miyao Y., Fujimoto K., Sugiyama S., Sakamoto T., Yoshimura M., and Ogawa H. Future adverse cardiac events can be predicted by persistently low plasma adiponectin concentrations in men and marked reductions of adiponectin in women after acute myocardial infarction. Atherosclerosis 194 (2007) 204-213
16. Maeda N., Takahashi M., Funahashi T., Kihara S., Nishizawa H., Kishida K., Nagaretani H., Matsuda M., Komuro R., Ouchi N., Kuriyama H., Hotta K., Nakamura T., Shimomura I., and Matsuzawa Y. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50 (2001) 2094-2099
17. Miyazaki Y., Mahankali A., Wajcberg E., Bajaj M., Mandarino L.J., and DeFronzo R.A. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. Journal of Clinical Endocrinology and Metabolism 89 (2004) 4312-4319
18. Mohlig M., Wegewitz U., Osterhoff M., Isken F., Ristow M., Pfeiffer A.F., and Spranger J. Insulin decreases human adiponectin plasma levels. Hormone and Metabolic Research 34 (2002) 655-658
19. Okamoto Y., Kihara S., Ouchi N., Nishida M., Arita Y., Kumada M., Ohashi K., Sakai N., Shimomura I., Kobayashi H., Terasaka N., Inaba T., Funahashi T., and Matsuzawa Y. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106 (2002) 2767-2770
20. Ouchi N., Kihara S., Arita Y., Maeda K., Kuriyama H., Okamoto Y., Hotta K., Nishida M., Takahashi M., Nakamura T., Yamashita S., Funahashi T., and Matsuzawa Y. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100 (1999) 2473-2476
21. Ouchi N., Kihara S., Arita Y., Okamoto Y., Maeda K., Kuriyama H., Hotta K., Nishida M., Takahashi M., Muraguchi M., Ohmoto Y., Nakamura T., Yamashita S., Funahashi T., and Matsuzawa Y. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 102 (2000) 1296-1301
22. Pereira R.I., and Draznin B. Inhibition of the phosphatidylinositol 3′-kinase signaling pathway leads to decreased insulin-stimulated adiponectin secretion from 3T3-L1 adipocytes. Metabolism 54 (2005) 1636-1643
23. Phillips S.A., Ciaraldi T.P., Kong A.P., Bandukwala R., Aroda V., Carter L., Baxi S., Mudaliar S.R., and Henry R.R. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes 52 (2003) 667-674
24. Rasouli N., Yao-Borengasser A., Miles L.M., Elbein S.C., and Kern P.A. Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression. American Journal of Physiology- Endocrinology and Metabolism 290 (2006) E42-E46
25. Smith U., Gogg S., Johansson A., Olausson T., Rotter V., and Svalstedt B. Thiazolidinediones (PPARgamma agonists) but not PPARalpha agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes. The Federation of American Societies for Experimental Biology Journal 15 (2001) 215-220 2001
26. Takeda K., Ichiki T., Tokunou T., Iino N., and Takeshita A. 15-Deoxy-delta 12,14-prostaglandin J2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells. Journal of Biological Chemistry 276 (2001) 48950-48955
27. Tiikkainen M., Hakkinen A.M., Korsheninnikova E., Nyman T., Makimattila S., and Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 53 (2004) 2169-2176
28. Tonelli J., Li W., Kishore P., Pajvani U.B., Kwon E., Weaver C., Scherer P.E., and Hawkins M. Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes 53 (2004) 1621-1629
29. Wynne A.M., Mocanu M.M., and Yellon D.M. Pioglitazone mimics preconditioning in the isolated perfused rat heart: a role for the prosurvival kinases PI3K and P42/44MAPK. Journal of Cardiovascular Pharmacology 46 (2005) 817-822
30. Yang W.S., Jeng C.Y., Wu T.J., Tanaka S., Funahashi T., Matsuzawa Y., Wang J.P., Chen C.L., Tai T.Y., and Chuang L.M. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 25 (2002) 376-380
31. Yu J.G., Javorschi S., Hevener A.L., Kruszynska Y.T., Norman R.A., Sinha M., and Olefsky J.M. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51 (2002) 2968-2974
32. Zhang B., Szalkowski D., Diaz E., Hayes N., Smith R., and Berger J. Potentiation of insulin stimulation of phosphatidylinositol 3-kinase by thiazolidinedione-derived antidiabetic agents in Chinese hamster ovary cells expressing human insulin receptors and L6 myotubes. Journal of Biological Chemistry 269 (1994) 25735-25741